Skip to content
Catalyst

knowcompoundsmetformin

Specimen compound organic compoundPlate I

Metformin

Nested hairline contours trace the electron density of one computed shape of metformin, teal at the edge warming to amber over the atoms.
fig. 1Metformin · electron density · PubChem CID 4091, computed 3D conformer
Formula
C4H11N5
Molar mass
129.167 g/mol
PubChem CID
4091
InChIKey
XZWYZXLIPXDOLR-UHFFFAOYSA-N

↓ lowered 5 findings in 3 endpoints

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
4
Limited
0
Very limited
1
Insufficient
0

How to read these marks

Fig. 2 Metformin CHEBI:6801 3 endpoints 5 findings
×1.60
Labels
CompoundInspector

Metformin

Most findings

  • All-cause mortality×2
  • Body mass index×2
  • Oesophageal cancer incidence×1

4 reference statements, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. All-cause mortality
  2. Body mass index
  3. Oesophageal cancer incidence
fig. 3 · 3 endpoints · 5 findingsno endpoint contested

02 · findings

What metformin moved, and by how much

  • OR odds ratio · MD mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Strength, at least

5 shown

  1. All-cause mortalityMoved: lowersEvidence: Moderatereplicated ×1Paper: PMID 412080452026
    Who
    adults with type 2 diabetes undergoing noncardiac surgery, metformin users vs non-users; secondary endpoint, unadjusted (before IPTW weighting), five-year follow-up horizon
    Dose studied
    not reported

    Before weighting, the 30-day and five-year mortalities after surgery were lower in the metformin group than in the non-metformin group (0.3% vs. 1.0%; P < 0.001 for 30-day mortality and 13.6% vs. 19.7%; P < 0.001 for five-year mortality).”

    Quoted verbatim from Association of preoperative metformin use with postoperative mortality and morbidity in type 2 diabetes patients undergoing noncardiac surgery: a retrospective cohort study.cohortPermalink
  2. All-cause mortalityMoved: lowersEffect, as reportedOR0.58[0.44 to 0.75]Evidence: Moderatereplicated ×1Paper: PMID 420878732026
    Who
    Adults with diabetes admitted with sepsis; pooled observational cohort studies comparing preadmission metformin users with non-users; mortality horizons pooled across studies (28-day, 30-day, 60-day, 90-day, 365-day, ICU and in-hospital)
    Dose studied
    not reported

    The results of the meta-analysis with a random-effects model showed that septic patients who received metformin prior to hospitalization had significantly lower mortality compared to those without metformin use (OR, 0.58; 95% CI, 0.44–0.75, P < 0.00001).”

    Quoted verbatim from Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.meta-analysisPermalink
  3. Oesophageal cancer incidenceMoved: lowersEffect, as reportedOR0.87Evidence: ModeratePaper: PMID 397748292025
    Who
    Patients with diabetes; 12 observational studies (cohort and case-control) of metformin use versus non-use, pooled incidence of esophageal cancer
    Dose studied
    not reported

    The random effects model showed that compared with the control groups, metformin might decrease EC incidence (OR = 0.87, P = 0.04).”

    Quoted verbatim from Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis.meta-analysisPermalink
  4. Body mass indexMoved: lowersEffect, as reportedMD−0.71[−1.23 to −0.19]Evidence: Moderatereplicated ×1Paper: PMID 405128732025
    Who
    Adults with type 1 diabetes on insulin, metformin versus placebo, each arm on standard insulin therapy; adult subgroup only, effect recorded at the 6-month timepoint (the sentence also reports a significant reduction at 3 months)
    Dose studied
    not reported

    Metformin significantly reduced BMI among adults at three (MD = −1.56 [95% CI: −2.05, −1.08], p = 0.00, I 2 = 0.00%) and six (MD = −0.71 [95% CI: −1.23, −0.19], p = 0.01, I 2 = 66.28%) months.”

    Quoted verbatim from An Updated Systematic Review and Meta-Analysis on the Efficacy and Safety of Metformin as Add-on Therapy to Insulin in Patients With Type 1 Diabetes.meta-analysisPermalink
  5. Body mass indexMoved: lowersEvidence: Very limitedreplicated ×1Paper: PMID 395094162025
    Who
    Patients receiving second-generation antipsychotics with antipsychotic-induced weight gain, pooled from double-blind placebo-controlled trials
    Dose studied
    not reported

    Additionally, metformin use resulted in a marked decrease in body mass index [-1.24 kg/m2 (95% CI: -1.70 to -0.77)].”

    Quoted verbatim from The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis.meta-analysisPermalink

No dose is advised.

  • OR odds ratio · MD mean difference. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · identity

Structure

fig. 4Metformin · 2D structure · ChEBI’s SMILES
Charge
0
SMILES
CN(C)C(=N)NC(=N)N

04 · figures · 1 plate

Plates

  • A dial of hairlines, each a peak of metformin's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
    fig. 5Metformin · MS2 [M+H]+ ESI-TOF positive · MassBank MSBNK-mFam-MC02_000764 (C. Broeckling, CC BY)

05 · reach

What it touches on the way

4 entities · assembled from reference reactions

  1. SLC47A1Protein17 paths · 16 endpointsinferred
  2. SLC22A2Protein5 paths · 5 endpointsinferred
  3. SLC22A1Protein3 paths · 3 endpointsinferred
  4. SLC47A2Protein1 path · 1 endpointinferred

Where it reaches

8 regions · transporter routes

  1. Female reproductivereproductive2 routesinferred
  2. Liverdigestive2 routesinferred
  3. Adrenal glandendocrine1 routeinferred
  4. Airway and sinusesrespiratory1 routeinferred
  5. Colon and rectumdigestive1 routeinferred
  6. Kidneyurinary1 routeinferred
  7. Lungrespiratory1 routeinferred
  8. Small intestinedigestive1 routeinferred

06 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reference statements
401 ProteinSLC22A1, SLC22A2, SLC47A1, SLC47A2inferred, one hop from metformin
Reactions · Rhea
3reactions
4Reference statements

What the reference databases state

Evidence key

Statements

4 statements

metformin is transported by each

3Reactions